Join the Oncology
Community
Follow Us:  

Vitality Signs

PTSD and Cancer: An Evolving Concept
December 14, 2011



Bookmark and Share

Most people conceptualize posttraumatic stress disorder (PTSD) as a condition rooted in horror on a grand scale: war, acts of terrorism, and cataclysmic natural disasters. Historically, when patients with cancer and other life-threatening diseases were plagued by intense distress about memories about their diagnosis or treatment, their symptoms didn't count.

Disease-related traumatic symptoms were explicitly excluded from the criteria for PTSD in the third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) of the American Psychiatric Association.

By 1994, when the DSM-IV was published, it recognized that trauma associated with the diagnosis and treatment of a major illness could lead to unshakable symptoms of re-experiencing, avoidance, and increased arousal that are serious enough to impair one’s functioning.

Today, the "bible" of psychiatric diagnosis is undergoing yet another revision, soon to be unveiled as DSM-V. The proposed PTSD criteria are likely to allow for the diagnosis not only in individuals who have experienced exposure to "actual or threatened" death, serious injury, or sexual violation, but also in those who have witnessed or heard about such exposure, or been connected with extreme exposure to reminders of such an event. The DSM-V will also include expanded symptom criteria for diagnosing PTSD in children, including pediatric cancer patients.

The National Cancer Institute notes that unlike some time-limited traumatic events, cancer may expose patients to "repeated traumas of undetermined length," followed by endless concern over recurrence.

A recent overview from Baylor University researchers speaks to the need to recognize and treat cancer-related PTSD, which has been reported to have a lifetime incidence of 3% to 22% among survivors.

The group’s findings, published in the Journal of Psychiatric Practice (2011:4:270-276), summarize findings from a number of studies. The authors determined that three clusters of symptoms central to a PTSD diagnosis were commonly found in studies of cancer survivors. These are:

  • Frequent intrusive thoughts (including flashbacks and nightmares): 16%-28%

  • High levels of emotional numbness and avoidance: 15%-34%

  • Hypervigilance and physiological arousal: 25%.

A threshold of symptoms from these clusters is required for diagnosis of PTSD, but many cancer patients may experience significant, sub-threshold reminders of the trauma of their experience.

Anyone who has listened well when survivors tell their stories will recognize the numb recounting of a particularly frightening procedure, the anxious catch in the breath while recalling the hearing of bad news delivered long ago.

The Baylor investigators point out that increasing rates of cancer and survivorship heighten the need for recognition and treatment of PTSD, which doesn’t simply fade away with time. Untreated, the disorder can perpetuate nonadherence, increase pain and disability, and undermine patients’ will to live, they note, "add[ing] morbidity to already difficult care."

Next week: Recognizing Resiliency and Risk in Cancer Patients

Current Issue


The Oncology Report Comprehensive reports and expert commentary on the latest advances in cancer treatment from the world's major oncology meetings.

Past issues, click here »


calendar
Jun 1 - 5
Chicago, IL
American Society of Clinical Oncology (ASCO): Annual Meeting
Jun 14 - 17
Amsterdam,
European Hematology Association (EHA): Annual Congress
Jun 18 - 21
Lake Tahoe, NV
American Association for Cancer Research (AACR): Pancreatic Cancer: Progress and Challenges
Jun 20 - 22
Milan,
European Institute of Oncology (IEO): 14th Milan Breast Cancer Conference
Jun 25 - 26
London,
Teenage Cancer Trust (TCT): International Conference
Jun 27 - 30
Barcelona,
European Society for Medical Oncology (ESMO) Conference: World Congress on Gastrointestinal Cancer
Jun 27 - 30
Boston, MA
American Association for Cancer Research (AACR): Chemical Systems Biology
Jun 28 - 30
New York, NY
Multinational Association of Supportive Care in Cancer (MASCC)/ International Society of Oral Oncology (ISOO): International Symposium
Jun 28 - 29
Paris,
WIN 2012 Symposium
Jul 7 - 10
Barcelona,
22nd Biennial Congress of the European Association for Cancer Research
More Calendar »